Dapansutrile-based Therapies for Chronic Diseases
Legal Citation
Summary of the Inventive Concept
Expanding the application of dapansutrile beyond melanoma treatment to address chronic respiratory diseases, cardiovascular diseases, neurodegenerative disorders, inflammatory bowel diseases, and osteoporosis.
Background and Problem Solved
The original patent disclosed methods for treating melanoma using dapansutrile. However, the patent's scope was limited to cancer treatment. The new inventive concept addresses the need for effective therapies in various chronic diseases, where inflammation and tissue damage play a significant role.
Detailed Description of the Inventive Concept
The new inventive concept leverages the anti-inflammatory and tissue-protective properties of dapansutrile to develop novel therapeutic approaches for chronic diseases. The system and method claims describe the administration of dapansutrile to subjects suffering from or at risk of these diseases, thereby reducing inflammation, promoting tissue healing, and improving disease outcomes. The composition claim outlines the use of dapansutrile as an active ingredient in formulations tailored to specific diseases.
Novelty and Inventive Step
The new claims introduce a significant shift in the application of dapansutrile, moving beyond cancer treatment to address a range of chronic diseases. This expansion of therapeutic scope is non-obvious and represents a substantial innovation over the original patent.
Alternative Embodiments and Variations
Alternative formulations, dosing regimens, and delivery methods could be explored to optimize the efficacy and safety of dapansutrile-based therapies. Additionally, combination therapies incorporating dapansutrile with other agents could be developed to enhance treatment outcomes.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential in the pharmaceutical industry, with applications in multiple disease areas and potential for market growth. The target markets include companies developing therapies for chronic respiratory diseases, cardiovascular diseases, neurodegenerative disorders, inflammatory bowel diseases, and osteoporosis.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical therapeutics, specifically drug repurposing and anti-inflammatory treatment strategies across multiple disease domains
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical researcher with expertise in drug mechanism of action, clinical pharmacology, and therapeutic development, holding advanced degrees in pharmacology or related biomedical sciences with knowledge of inflammatory pathways and drug repositioning techniques
Obviousness Rationale
A skilled practitioner would recognize dapansutrile's anti-inflammatory mechanism as broadly applicable across multiple disease states involving inflammatory processes. The source patent's focus on melanoma treatment establishes the drug's therapeutic potential, making its extension to other inflammatory conditions a predictable and logical progression. The PTD's variations represent systematic exploration of dapansutrile's underlying pharmacological properties through well-established drug development methodologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,529 |
|---|---|
| Title | Methods for treating melanoma |
| Assignee(s) | OLATEC THERAPEUTICS, INC. |